4-Antibody to collaborate with Boehringer Ingelheim
Long-term collaboration for targets in various disease indications
Swiss biotech firm 4-Antibody is to collaborate with Boehringer Ingelheim to discover and develop fully human therapeutic antibodies for a number of targets in various disease indications.
4-Antibody will use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the development of antibodies against novel targets nominated by Boehringer Ingelheim.
Boehringer Ingelheim will pay 4-Antibody up to €177.5m, including upfront and milestone payments. Further financial details were not disclosed.
Ulf Grawunder, co-founder and chief scientific officer of 4-Antibody, said: ‘This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody’s fully human antibody discovery and engineering platforms to create valuable potential new drug candidates.’
